AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20705157
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg DRSP/30 mcg EE (Yasmin)
Trial: 20705157
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg CMA/30 mcg EE (Belara)
Trial: 20705157
Drug: 75 mcg
RxNorm normalized name: Levo-T 75 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mcg GSD/30 mcg EE (Minulet)
Trial: 20705157
Drug: 150 mcg
RxNorm normalized name: kelp 150 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mcg DSG/30 mcg EE (Practil 21)
Trial: 17400976
Drug: Immediate‐release oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate‐release oxycodone 5 mg and acetaminophen 325 mg (Percocet‐5) four times daily
Trial: 17400976
Drug: Controlled‐release oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled‐release oxycodone 10 mg (OxyContin) every 12 hr and placebo twice daily
Trial: 7880708
Drug: 51W89 (incremental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51W89 (incremental doses of 94 (19) micrograms kg-1)
Trial: 1920787
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of buprenorphine at 0.2 mg.24 hr‐1
Trial: 1920787
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of pethidine at 50 mg.hr‐1
Trial: 6811447
Drug: procetofen (300‐600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: procetofen (300‐600 mg daily) for 6 months
Trial: 30667285
Drug: Culturally Adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Adapted Treatment (CAT)
Trial: 30667285
Drug: Standard Evidence-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Evidence-Based Treatment (EBT)
Trial: 22915624
Drug: Intravenous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous abatacept (∼10 mg/kg)
Trial: 21505147
Drug: Metreleptin (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.08 mg·kg(‐1)·day(‐1) for 10 wk)
Trial: 21505147
Drug: Metreleptin (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (initial dose: 0.08 mg·kg(‐1)·day(‐1) for 3 mo, increased to 0.12 mg·kg(‐1)·day(‐1) if menstruation did not occur)
Trial: 9333110
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/day orally for 10 days)
Trial: 9333110
Drug: Perphenazine (0.11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (0.11 mg/kg orally) after paroxetine pretreatment
Trial: 8471404
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg day‐1)
Trial: 8471404
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg day‐1)
Trial: 18190629
Drug: Variable dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable dosage of sildenafil (25, 50, 100 mg) or vardenafil (5, 10, 20 mg) determined by NPTR
Trial: 18190629
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose sildenafil 25 mg or vardenafil 5 mg
Trial: 18190629
Drug: Variable dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable dosage of sildenafil or vardenafil
Trial: 18190629
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose sildenafil or vardenafil
Trial: 7659137
Drug: Flutrimazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutrimazole 1% dermal cream
Trial: 7659137
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% dermal cream
Trial: 26888731
Drug: Allogeneic-adipose-derived mesenchymal
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic-adipose-derived mesenchymal stem cells (ALLO-ASCs) injected into the anal sphincter (doses: 3 × 10(7), 6 × 10(7), 9 × 10(7) cells)
Trial: 26888731
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline injection mixed with fibrin glue (placebo)
Trial: 25075802
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) delivered by a child anxiety specialist in the primary care clinic
Trial: 7615189
Drug: Mesalamine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (1.5 g twice a day)
Trial: 823950
Drug: Thyrotropin releasing
RxNorm normalized name: Thyrotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin releasing hormone (TRH)
Trial: 23815739
Drug: SMART Arm
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART Arm training with OT-stim and usual therapy
Trial: 23815739
Drug: SMART Arm
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART Arm training without OT-stim and usual therapy
Trial: 11757182
Drug: Radiotherapy doses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy doses of 26-34 Gy
Trial: 11757182
Drug: Radiotherapy doses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy doses of 36 Gy
Trial: 11757182
Drug: Radiotherapy doses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy doses of 40 Gy or more
Trial: 25794092
Drug: Simethicone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (200 mg)
Trial: 21147298
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration (LC) contrast medium (150 mg iodine/ml)
Trial: 21147298
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration (HC) contrast medium (300 mg iodine/ml)
Trial: 18942560
Drug: Audiovisual support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audiovisual support in adjunct to written informative form
Trial: 8839907
Drug: Carboplatin/5-fluorouracil concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/5-fluorouracil concurrent with radiotherapy (group I)
Trial: 6370157
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of 4 units of platelet concentrates at the end of bypass
Trial: 6370157
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of platelet concentrates
Trial: 31481568
Drug: Systematic medication
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic medication review intervention using the 'Systematic Tool to Reduce Inappropriate Prescribing'‐Assistant (STRIPA)
Trial: 31481568
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care sham intervention (GP discusses medication list completeness)
Trial: 31481568
Drug: Systematic medication
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic medication review intervention
Trial: 29489977
Drug: G‐CSF injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF injection for 3 days after chemotherapy
Trial: 26458034
Drug: Generic glatiramer
RxNorm normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic glatiramer acetate (20 mg)
Trial: 26458034
Drug: Brand glatiramer
RxNorm normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand glatiramer acetate (20 mg)
Trial: 15161434
Drug: Gemcitabine (Gemzar®)
RxNorm normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (Gemzar®) as a single agent
Trial: 15161434
Drug: Gemcitabine in
RxNorm normalized name: gemcitabine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine in combination with platinum-based chemotherapy
Trial: 18084949
Drug: Gemcitabine in
RxNorm normalized name: gemcitabine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine in combination with radiotherapy
Trial: 12075638
Drug: IV ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ephedrine infusion (5 mg.min(‐1) immediately after spinal injection)
Trial: 12075638
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of IV ephedrine (10 mg in case of hypotension)
Trial: 10458204
Drug: Docetaxel at
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel at 100 mg/m2 administered as a 1-hour intravenous infusion every 3 weeks
Trial: 10458204
Drug: Docetaxel at
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel at 100 mg/m2 or 75 mg/m2
Trial: 2180328
Drug: Antidepressants or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants or placebo (3-6 weeks treatment)
Trial: 6345340
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (10 g)
Trial: 22959457
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (IMP) 25-50 mg/d
Trial: 22959457
Drug: 8% Crinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% Crinone vaginal gel
Trial: 20492837
Drug: OROS-MPH (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-MPH (titrated to 72 mg/d)
Trial: 18541000
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice-daily
Trial: 18541000
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg twice-daily
Trial: 18541000
Drug: Apixaban 20
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 20 mg once-daily
Trial: 11220454
Drug: Electrophysiologic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysiologic testing (EP)‐guided therapy with implantable defibrillator
Trial: 8994421
Drug: Direct NO
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct NO donors (infusion of linsidomine followed by oral molsidomine)
Trial: 1587069
Drug: Oral diltiazem
RxNorm normalized name: diltiazem Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diltiazem
Trial: 30396627
Drug: Cinnamon (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (1000 mg capsules)
Trial: 30396627
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mg starch capsules)
Trial: 22196836
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy intervention (brief, nurse-delivered during hospitalization with a 1-week booster phone call)
Trial: 12608624
Drug: Inhaled anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthetics and/or radiation exposure
Trial: 9649457
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg AM and 20 mg PM) for 7 days
Trial: 7978090
Drug: Fenfluramine (60‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (60‐mg oral dose)
Trial: 3263508
Drug: Continuous-infusion IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion IL-2 at 3 X 10(6) U/m2 per day
Trial: 30063644
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg (single dose)
Trial: 30063644
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg (single dose)
Trial: 30063644
Drug: Nebivolol (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (weekly administration)
Trial: 30063644
Drug: Irbesartan (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (weekly administration)
Trial: 22801017
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (Tsang‐Erh‐San extract granules and Houttuynia extract powder)
Trial: 955230
Drug: Full-strength dimethylsulfoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength dimethylsulfoxide (DMSO) and potent topical corticosteroids
Trial: 31217178
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) diclofenac (75 mg)
Trial: 31217178
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) diclofenac (100 mg)
Trial: 26685923
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) (n=21), received no treatment.
Trial: 23377231
Drug: Bilateral movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral movement therapy
Trial: 23377231
Drug: Unilateral movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral movement therapy
Trial: 19656689
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 2.5% w/w Reseda luteola extract (s-RE)
Trial: 17403977
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of olanzapine
Trial: 17403977
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of olanzapine
Trial: 17403977
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of risperidone
Trial: 17403977
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of risperidone
Trial: 31059991
Drug: Control (standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard-of-care pharmacotherapy alone)
Trial: 23328710
Drug: Cinacalcet with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet with low-dose active vitamin D
Trial: 19486273
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (daily use in 65% of children, occasional use in 12%)
Trial: 19486273
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of melatonin treatment
Trial: 11842864
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate (1200 mg) and glucosamine hydrochloride (1500 mg) daily for 12 weeks
Trial: 31062834
Drug: Vortioxetine, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine, 15 mg/day (n=36)
Trial: 31062834
Drug: Other common
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other common antidepressants (n=72)
Trial: 31062834
Drug: Other common
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other common antidepressants
Trial: 21560476
Drug: Direct intramyocardial
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct intramyocardial injection of autologous bone marrow cells (CD34+ selected cells)
Trial: 21560476
Drug: Direct intramyocardial
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct intramyocardial injection of autologous bone marrow cells (all mononuclear cells)
Trial: 21560476
Drug: Direct intramyocardial
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct intramyocardial injection of autologous bone marrow cells (both CD34+ selected cells and all mononuclear cells)
Trial: 19702080
Drug: Lixu Jieyu
RxNorm normalized name: Lixudebart
DrugBank: Lixudebart (DB19244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixu Jieyu Recipe (LJR), 100 mL twice a day for 3 months
Trial: 19702080
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B tablets (10 mg twice a day), adenosine triphosphate (ATP, 20 mg thrice a day), and Oryzanol tablets (20 mg thrice a day)
Trial: 12919762
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin combined with octenidine dihydrochloride bodywash over a period of five days
Trial: 8202722
Drug: rHuEPO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO treatment in responding patients
Trial: 8202722
Drug: rHuEPO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO therapy overall
Trial: 28608311
Drug: Allopurinol 600
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 600 mg administered 24 hours before and immediately before the procedure
Trial: 28608311
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 24 hours before and immediately before the procedure
Trial: 21258075
Drug: Levosimendan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (12 µg bolus followed by an infusion of 0.2 µg kg(‐1) min(‐1))
Trial: 16799350
Drug: TIVA (Total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (Total Intravenous Anesthesia with Propofol)
Trial: 10887047
Drug: Activated Charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated Charcoal (7.5 g)
Trial: 10887047
Drug: Activated Charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated Charcoal (15 g)
Trial: 10887047
Drug: Diethylcarbamazine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (150 mg)
Trial: 8397726
Drug: Gamma-hydroxybutyric acid
RxNorm normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-hydroxybutyric acid (GHB) 25 mg/kg orally
Trial: 8397726
Drug: GHB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB treatment suspended after 8 days
Trial: 23829056
Drug: Permethrin 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 2.5% cream (two applications with one week interval)
Trial: 17283867
Drug: Eccentric dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric dosing of nitrates
Trial: 17283867
Drug: Continuous dosing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dosing of nitrates
Trial: 1684481
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin A formulations
Trial: 28402756
Drug: Instrumented manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumented manual therapy plus self‐stretching
Trial: 26311526
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose radiotherapy
Trial: 26311526
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose post-operative radiotherapy
Trial: 17305763
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg once daily for 4 weeks
Trial: 11158034
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of recombinant human GHRH-(1-44)-amide